Polypharmacology-Driven Discovery of ZAK-I-57: A Potent Multi-Targeted Benzoxazinone Small Molecule for...

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high mortality and resistance to existing therapies.
• The complex pathogenesis of HCC necessitates a multitargeted, polypharmacological therapeutic strategy for improved efficacy.
• Current treatments for HCC, such as sorafenib, have limitations, underscoring the need for novel therapeutic agents.

Purpose of the Study:

• To evaluate the multitargeted and polypharmacological potential of ZAK-I-57, a benzoxazinone derivative, as a novel therapeutic agent for hepatocellular carcinoma (HCC).
• To assess the in vitro and in vivo efficacy of ZAK-I-57 in preclinical HCC models and compare its performance against sorafenib.

Main Methods:

• In vitro antiproliferative assays were conducted on HCC cell lines.
• In vivo efficacy was evaluated using PLC/PRF/5 tumor-bearing and patient-derived tumor xenograft (PDTX) mouse models.
• Tumor suppressive effects were compared to sorafenib at doses of 15 and 30 mg/kg.
• Molecular mechanisms were investigated using Western blot analysis to assess EGFR, c-Myc, Bax, and Bcl-2 expression.
• ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties and safety profiles were evaluated.

Main Results:

• ZAK-I-57 demonstrated significant in vitro inhibition of HCC cell proliferation.
• In vivo studies showed superior tumor suppressive effects of ZAK-I-57 compared to sorafenib in both tumor models.
• Western blot analysis revealed that ZAK-I-57 downregulated oncogenic proteins EGFR and c-Myc.
• ZAK-I-57 promoted apoptosis by increasing Bax and decreasing Bcl-2 expression.
• The compound exhibited excellent ADMET properties, including high gastrointestinal absorption and good lipophilicity, with no significant off-target toxicity.

Conclusions:

• ZAK-I-57 is a potent multitargeted therapeutic agent with significant preclinical efficacy against hepatocellular carcinoma.
• Its mechanism involves downregulation of key oncogenic proteins and induction of apoptosis.
• ZAK-I-57 possesses favorable pharmacokinetic and safety profiles, suggesting its potential for clinical development.
• Further clinical investigation is warranted to establish ZAK-I-57 as a viable treatment option for HCC patients.